Actoxumab (0.1-10 mg/kg or 50 mg/kg; i.p.; single dose) shows protective effect in multiple murine models of clostridium difficile infection (CDI), including systemic and local (gut) toxin challenge models, as well as primary and recurrent models of infection in mice[1].
Actoxumab shows a synergy with Bezlotoxumab, and (combination dosage of 3, 30, 300 μg/mouse; i.p.; single dose) prevents both epithelial damage and inflammatory disease[1].
| Animal Model: | Murine C. difficile infection model in CD1 and C57BL/6 mice (6-8 weeks old)[1] |
| Dosage: | Combination dosage of 3, 30, 300 μg/mouse; or ~0.1, 1, and 10 mg/kg |
| Administration: | Intraperitoneal injection; single dose; 1 hour before 25 ng TcdA or 25 ng TcdB challenge |
| Result: | Protected with Bezlotoxumab, against systemic and intestinal toxin challenge in mice. |
| Animal Model: | Ileal loop model in CD1 and C57BL/6 mice (6-8 weeks old)[1] |
| Dosage: | 50 mg/kg; or combined with 50 mg/kg Bezlotoxumab |
| Administration: | Intraperitoneal injection; single dose |
| Result: | Significantly reduced fluid accumulation in toxin-challenged mice (109.4 mg/cm). |
